PT880

N/A

Report date: 2026/03/19 17:18:06

Base Information

Drug NamePT880

Drug Alias NamePT880

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionClaudin-18 splice variant 2 antagonistsAnti-CD3

TargetsClaudin-18 splice variant 2T cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPhanes Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesPhanes Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A